lg 100268 has been researched along with Invasiveness, Neoplasm in 2 studies
LG 100268: a retinoid X receptor (RXR) selective compound; structure given in first source
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Suh, N | 1 |
| Lamph, WW | 2 |
| Glasebrook, AL | 1 |
| Grese, TA | 1 |
| Palkowitz, AD | 1 |
| Williams, CR | 1 |
| Risingsong, R | 1 |
| Farris, MR | 1 |
| Heyman, RA | 1 |
| Sporn, MB | 1 |
| Li, Y | 1 |
| Zhang, Y | 1 |
| Hill, J | 1 |
| Shen, Q | 1 |
| Kim, HT | 1 |
| Xu, X | 1 |
| Hilsenbeck, SG | 1 |
| Bissonnette, RP | 1 |
| Brown, PH | 1 |
2 other studies available for lg 100268 and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene, and a new rexinoid, LG 100268.
Topics: Animals; Anticarcinogenic Agents; Cells, Cultured; Drug Synergism; Drug Therapy, Combination; Female | 2002 |
The Rexinoid LG100268 prevents the development of preinvasive and invasive estrogen receptor negative tumors in MMTV-erbB2 mice.
Topics: Animals; Anticarcinogenic Agents; Cell Line, Tumor; Cyclin D1; Female; Humans; Immunohistochemistry; | 2007 |